DE68928857D1 - Monoklonale Antikörper, die mit Cachectin reagieren - Google Patents

Monoklonale Antikörper, die mit Cachectin reagieren

Info

Publication number
DE68928857D1
DE68928857D1 DE68928857T DE68928857T DE68928857D1 DE 68928857 D1 DE68928857 D1 DE 68928857D1 DE 68928857 T DE68928857 T DE 68928857T DE 68928857 T DE68928857 T DE 68928857T DE 68928857 D1 DE68928857 D1 DE 68928857D1
Authority
DE
Germany
Prior art keywords
monoclonal antibodies
cachectin
react
antibodies
cell lines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68928857T
Other languages
English (en)
Other versions
DE68928857T2 (de
Inventor
George Kuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE68928857D1 publication Critical patent/DE68928857D1/de
Application granted granted Critical
Publication of DE68928857T2 publication Critical patent/DE68928857T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE68928857T 1988-07-18 1989-07-18 Monoklonale Antikörper, die mit Cachectin reagieren Expired - Fee Related DE68928857T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22020688A 1988-07-18 1988-07-18

Publications (2)

Publication Number Publication Date
DE68928857D1 true DE68928857D1 (de) 1999-01-07
DE68928857T2 DE68928857T2 (de) 1999-08-05

Family

ID=22822529

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68928857T Expired - Fee Related DE68928857T2 (de) 1988-07-18 1989-07-18 Monoklonale Antikörper, die mit Cachectin reagieren

Country Status (16)

Country Link
US (1) US5658803A (de)
EP (1) EP0351789B1 (de)
JP (1) JP2638652B2 (de)
AT (1) ATE173766T1 (de)
AU (1) AU626572B2 (de)
CA (1) CA1340018C (de)
DE (1) DE68928857T2 (de)
DK (1) DK69890A (de)
ES (1) ES2124209T3 (de)
FI (1) FI101937B1 (de)
IL (1) IL90990A (de)
NO (1) NO179615C (de)
NZ (1) NZ229922A (de)
PT (1) PT91201B (de)
WO (1) WO1990000902A1 (de)
ZA (1) ZA895372B (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959087A (en) 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
AU640400B2 (en) * 1989-08-07 1993-08-26 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US6448380B2 (en) 1989-08-07 2002-09-10 Peptech Limited Tumor necrosis factor antibodies
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
EP0487610B1 (de) * 1989-08-16 2000-02-09 Chiron Corporation Prohormonspaltungsplatzblockierungsantikörper
DE4037604A1 (de) * 1990-04-25 1991-10-31 Bayer Ag Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
EP0592423B1 (de) * 1990-08-06 2000-11-15 Chiron Corporation Verfahren zum nachweis von cytokinkonvertasehemmern
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
JPH06505969A (ja) * 1991-01-11 1994-07-07 レプリジェン　コーポレーション 炎症性損傷防止方法
EP1857554A1 (de) * 1991-03-18 2007-11-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP0525570A3 (en) * 1991-07-31 1993-10-06 Miles Inc. Anti-idiotypic antibodies that mimic tnf
DE69321909T2 (de) * 1992-08-28 1999-04-01 Bayer Ag Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden
DE69405102T2 (de) 1993-06-03 1998-01-15 Therapeutic Antibodies Inc Antikoerperfragmente in therapie
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
WO1996008516A1 (en) * 1994-09-15 1996-03-21 Verigen, Inc. PORCINE ANTIBODIES TO TNF-α(ALPHA)
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
WO1997029131A1 (en) 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
DE19746868A1 (de) * 1997-10-23 1999-04-29 Knoll Ag Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
MXPA05005921A (es) 2002-12-02 2005-10-19 Abgenix Inc Anticuerpos dirigidos a factor de necrosis tumoral y sus usos.
US20050045635A1 (en) * 2003-09-03 2005-03-03 Jane Dong Containers for storing articles
TWI439284B (zh) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
CA2903138A1 (en) 2005-05-16 2006-11-23 Abbvie Biotechnology Ltd. Use of tnfa inhibitor for treatment of erosive polyarthritis
EP1963367A4 (de) * 2005-12-06 2009-05-13 Amgen Inc Reinigungsschritte in mehrstufigen proteinreinigungsverfahren
KR20090005315A (ko) 2006-04-05 2009-01-13 애보트 바이오테크놀로지 리미티드 항체 정제
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2666472A3 (de) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
CN104188911A (zh) 2008-01-15 2014-12-10 Abbvie德国有限责任两合公司 粉末状蛋白质组合物及其制备方法
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2898354C (en) 2013-01-25 2017-11-21 Thymon, Llc Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
EP3052640A2 (de) 2013-10-04 2016-08-10 AbbVie Inc. Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JP2020506916A (ja) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
KR20190115042A (ko) 2017-02-07 2019-10-10 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
EP3972690A4 (de) 2019-05-23 2023-07-05 Janssen Biotech, Inc. Verfahren zur behandlung einer entzündlichen darmerkrankung mit einer kombinationstherapie von antikörpern gegen il-23 und tnf-alpha

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4684623A (en) * 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
EP0249618A1 (de) * 1985-12-05 1987-12-23 Biogen N.V. Mischungen von tumor-nekrose-faktoren mit antibiotika und verfahren zur behandlung von tumoren
US4834976A (en) * 1986-07-03 1989-05-30 Genetic Systems Corporation Monoclonal antibodies to pseudomonas aeruginosa flagella
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung

Also Published As

Publication number Publication date
JPH03501330A (ja) 1991-03-28
PT91201B (pt) 1996-12-31
FI901344A0 (fi) 1990-03-16
PT91201A (pt) 1990-02-08
EP0351789A3 (de) 1990-08-01
ATE173766T1 (de) 1998-12-15
DK69890D0 (da) 1990-03-16
FI101937B (fi) 1998-09-30
NO901247L (no) 1990-03-16
EP0351789B1 (de) 1998-11-25
US5658803A (en) 1997-08-19
FI101937B1 (fi) 1998-09-30
ZA895372B (en) 1990-04-25
AU626572B2 (en) 1992-08-06
DK69890A (da) 1990-05-15
DE68928857T2 (de) 1999-08-05
WO1990000902A1 (en) 1990-02-08
NZ229922A (en) 1992-04-28
NO179615B (no) 1996-08-05
AU3970389A (en) 1990-02-19
IL90990A (en) 1994-10-21
NO901247D0 (no) 1990-03-16
ES2124209T3 (es) 1999-02-01
JP2638652B2 (ja) 1997-08-06
IL90990A0 (en) 1990-02-09
NO179615C (no) 1996-11-13
EP0351789A2 (de) 1990-01-24
CA1340018C (en) 1998-09-01

Similar Documents

Publication Publication Date Title
ATE173766T1 (de) Monoklonale antikörper, die mit cachectin reagieren
AU3035189A (en) Ultrasonic contrast agents, process for producing them and their use as diagnostic and therapeutic agents
DE68908927D1 (de) Epitaxiereaktor mit Planetenbewegung.
DE68912334D1 (de) Immunokonjugate für krebs-diagnose und -therapie.
CA2192079A1 (en) Human Monoclonal Antibodies Specific to Cell Cycle Independent Glioma Surface Antigen
EP0341684A3 (en) Human monoclonal antibody, hybridoma producing the same and pharmaceutical
NO873634L (no) Hybrid acryl-stjerne polymerer, og fremgangsmaate for fremstilling derav.
FI853389L (fi) Tumoerlaekemedel och foerfarande foer dess framstaellning.
ATE125870T1 (de) Hiv-spezifische monoklonale antikörper und hybridome zu ihrer herstellung.
EP0363712A3 (en) Hybrid monoclonal antibodies, their production and use
IL96369A0 (en) Decapeptide,monoclonal antibodies directed thereto and their use in diagnosis
ATE58397T1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
TR25221A (tr) ISLAH EDILMIS YUMUSAKLIGA SAHIP YAGLANMIS DERILER VE BUNLARIN üRETILMESINE MAHSUS USUL.
NO885818D0 (no) Termoplastiske olefiner og fremgangsmaate for fremstilling derav.
DE68904336T2 (de) Anti-humankrebsproteinkomplexe, deren herstellung und verwendung.
IL75793A0 (en) Monoclonal antibodies against human ifn-ypsilon,their preparation and their use and hybrid cell lines producing these antibodies
DE358739T1 (de) Monoklonale antikoerper gegen glykosyliertes albumin, hybride zellinien, die diese antikoerper produzieren, sowie deren verwendung.
ZA897023B (en) Hybrid monoclonal antibodies,their production and use
ATE67567T1 (de) Hydrostatisch mechanisches leistungsverzweigungsgetriebe.
IT8523549V0 (it) Dispositivo di applicazione del tessuto sull'anima di avvolgimento, in particolare per stazioni di avvolgimento automatico di tessuto in pezza continua e procedimento di applicazione del tessuto.
ES1006440Y (es) Plantilla terapeutica.
FI884370A (fi) Wobbler foer graesbevuxna vatten.
ATE84421T1 (de) Anti-humankrebsproteinkomplexe, deren herstellung und verwendung.
FI880188A0 (fi) Wobbler med flere funktioner.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee